Last reviewed · How we verify

Tisseel Fibrin Sealant

Massachusetts General Hospital · FDA-approved active Small molecule

Tisseel is a fibrin sealant that mimics the final step of the coagulation cascade to form a stable clot and seal tissue surfaces.

Tisseel is a fibrin sealant that mimics the final step of the coagulation cascade to form a stable clot and seal tissue surfaces. Used for Hemostasis and tissue sealing in general surgery, Hemostasis in cardiac surgery, Hemostasis in vascular surgery.

At a glance

Generic nameTisseel Fibrin Sealant
SponsorMassachusetts General Hospital
Drug classFibrin sealant
TargetFibrinogen (substrate for thrombin-catalyzed polymerization)
ModalitySmall molecule
Therapeutic areaSurgery/Hemostasis
PhaseFDA-approved

Mechanism of action

Tisseel consists of two components—fibrinogen and thrombin—that when mixed together polymerize fibrinogen into fibrin, creating a biological adhesive that seals wounds and surgical sites. This mimics the natural hemostatic process and provides both hemostasis and tissue adhesion without requiring sutures or staples in many applications.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: